Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
Sponsor: AbbVie
Summary
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma. This study will assess adverse events and change in disease activity in adult Korean participants with DLBCL under routine clinical practice. Epcoritamab is an approved drug for the treatment of DLBCL and FL. Approximately 175 adult participants who are prescribed epcoritamab by their doctors will be enrolled sites in Korea. Participants will receive epcoritamab as prescribed by their physician. Participants will be followed for up to 24 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Official title: Post Marketing Safety Study to Evaluate the Safety and Effectiveness of Epcoritamab in Korean Adult Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
175
Start Date
2026-10-02
Completion Date
2029-11
Last Updated
2026-10-07
Healthy Volunteers
No